local_hospital

University Hospital Bratislava

Address
lock Available on a paid plan

Cardiovascular and Heart Failure Research

At University Hospital Bratislava, clinical trials in cardiovascular diseases focus on major conditions such as atherosclerotic cardiovascular disease, heart failure, and hypertension. These studies are designed to test new ways to lower cardiovascular risk, prevent serious events, and improve long-term heart health.

  • Studies on atherosclerotic cardiovascular disease and prevention of major heart attacks and strokes
  • Research in heart failure and related kidney complications
  • Trials in hypertension and broader cardiovascular risk reduction

This research helps evaluate whether emerging therapies can better protect patients with established heart disease or those at high risk of future events.

Neurology and Neurodegenerative Disorders

The site conducts important studies in nervous system diseases and mental disorders, especially multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The main goal is to improve symptom control, slow disease activity, and support better daily functioning for people living with chronic neurological conditions.

  • Multiple sclerosis research focused on relapse control and long-term disease management
  • Parkinson’s disease trials aimed at improving motor symptoms and treatment stability
  • Alzheimer’s disease studies addressing agitation, psychosis, and cognitive decline

This area reflects a strong interest in both disease-modifying therapies and treatments that improve quality of life for patients and caregivers.

Oncology and Hematology Studies

The clinical research portfolio includes neoplasms and hemic and lymphatic diseases, with trials in non-small cell lung cancer, multiple myeloma, acute lymphoblastic leukemia, and other advanced cancers. These studies aim to test new cancer treatments, compare them with current standards, and improve outcomes for patients with difficult-to-treat disease.

  • Non-small cell lung cancer studies in locally advanced, metastatic, and biomarker-defined disease
  • Multiple myeloma and leukemia research for relapsed or newly diagnosed blood cancers
  • Trials exploring better treatment effectiveness and survival outcomes in advanced malignancies

This work supports the development of more effective cancer therapies and broader access to innovative oncology care.

Kidney and Immune-Mediated Disease Research

A significant part of the research at this hospital centers on immune system diseases and nutritional and metabolic diseases, particularly IgA nephropathy, chronic kidney disease, and related inflammatory conditions. These trials are mainly designed to preserve kidney function, reduce protein loss in urine, and improve disease control in immune-driven disorders.

  • IgA nephropathy and other glomerular diseases affecting kidney health
  • Chronic kidney disease studies looking at progression and proteinuria
  • Immune-targeted research in diseases driven by abnormal inflammation and antibody activity

The focus is on finding therapies that may slow progression and offer better long-term protection for kidney patients.

Eye Disease and Vision Research

Clinical trials in eye diseases at University Hospital Bratislava include diabetic macular edema, neovascular age-related macular degeneration, and thyroid eye disease. These studies are intended to improve vision outcomes, reduce disease-related damage, and assess new approaches for chronic eye conditions.

  • Diabetic macular edema and diabetic eye disease linked to diabetes
  • Wet age-related macular degeneration and other retinal disorders
  • Thyroid eye disease research focused on reducing swelling and eye protrusion

This field combines treatment evaluation with efforts to preserve sight and improve everyday visual function.

Respiratory, Dermatology, and Other Specialized Conditions

The site also participates in trials across respiratory tract diseases, musculoskeletal diseases, and selected congenital and hereditary disorders. Research includes conditions such as chronic obstructive pulmonary disease, viral lung infections, bullous pemphigoid, and hidradenitis suppurativa, with the aim of improving treatment effectiveness and symptom relief.

  • Chronic obstructive pulmonary disease and severe viral lung infection studies
  • Bullous pemphigoid and hidradenitis suppurativa research in inflammatory skin disease
  • Trials in less common disorders such as multifocal motor neuropathy, hypophosphatasia, and spasticity

These studies show a broad interest in both common chronic illnesses and rarer conditions that still need better treatment options.

Metabolic, Gastrointestinal, and Mental Health Research

Additional trials address digestive system diseases, nutritional and metabolic diseases, and psychiatry and psychology. Key areas include non-alcoholic steatohepatitis, obesity, and symptoms linked to Alzheimer’s disease, such as agitation and psychosis, reflecting a strong interest in both physical and behavioral health.

  • Non-alcoholic steatohepatitis and liver-related disease progression
  • Overweight and obesity research tied to cardiovascular and metabolic risk
  • Psychiatric symptoms in Alzheimer’s disease, including agitation and psychosis

These trials aim to improve disease management across interconnected metabolic, liver, and mental health conditions.

Site Overview

assignment
89
connected trials
corporate_fare
37
sponsors
science
161
IMPs

Activity Indicator

Last 6 months

8
Trials started
0% vs previous period.
8
Trials started 6–12 months ago
89
Total trials linked
Highly Active
trending_flatStable0%
2
1
2
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 15 therapeutic areas and 15 of 161 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 160 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
38
Sponsors (total)
37
Active sponsors
20

Sponsor Network

Top 20 by active trials.

lock +19 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +15 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 353 other sites in Slovakia

description
Trial volume
89
Outperforms 100% of sites
public
Therapeutic diversity
17areas
Outperforms 100% of sites
groups
Sponsor diversity
37sponsors
Outperforms 100% of sites

Therapeutic Area Benchmark — Slovakia

Select a therapeutic area to compare against other sites in Slovakia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Slovakia

Market Share

Country: Slovakia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Hospital Bratislava

lock Showing 1 of 89 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein OcclusionBayer AGPhase IIINot RecruitingSep 2023May 2025

IMP list

lock Showing 1 of 161 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Aflibercept6Unknown2021-08-272026-03-31

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.